

Chemometric Approaches for Developing Infrared Nanosensors to Image Anthracyclines

Jackson Travis Del Bonis-O'Donnell, Rebecca Pinals, Sanghwa Jeong, Ami Thakrar, Russ Wolfinger, and Markita P Landry

Biochemistry, **Just Accepted Manuscript** • DOI: 10.1021/acs.biochem.8b00926 • Publication Date (Web): 27 Nov 2018

Downloaded from <http://pubs.acs.org> on December 2, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



CHEMOMETRIC APPROACHES FOR DEVELOPING INFRARED NANOSENSORS TO IMAGE ANTHRACYCLINES

Jackson Travis Del Bonis-O'Donnell¹, Rebecca L. Pinals¹, Sanghwa Jeong¹, Ami Thakrar¹, Russ D. Wolfinger^{2,3}, Markita P. Landry^{*1,4-6}

¹ Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA 94720

² SAS Institute Inc. Cary, NC 27513

³ Department of Statistics, North Carolina State University, Raleigh, NC 27695

⁴ Innovative Genomics Institute (IGI), Berkeley, CA 94720

⁵ California Institute for Quantitative Biosciences, QB3, University of California, Berkeley, CA 94720


⁶ Chan-Zuckerberg Biohub, San Francisco, CA 94158

*Corresponding author, e-mail: landry@berkeley.edu

ABSTRACT

Generation, identification, and validation of optical probes to image molecular targets in a biological milieu remains a challenge. Synthetic molecular recognition approaches leveraging the intrinsic near-infrared fluorescence of single-walled carbon nanotubes is a promising approach for long-term biochemical imaging in tissues. However, generation of nanosensors for selective imaging of molecular targets requires a heuristic approach. Here, we present a chemometric platform for rapidly screening libraries of candidate single-walled carbon nanotube nanosensors against biochemical analytes to quantify fluorescence response to small molecules including vitamins, neurotransmitters, and chemotherapeutics. We further show this approach can be leveraged to identify biochemical analytes that selectively modulate the intrinsic near-infrared fluorescence of candidate nanosensors. Chemometric analysis thus enables identification of nanosensor-analyte 'hits' and also nanosensor fluorescence signaling modalities such as wavelength-shifts that are optimal for translation to biological imaging. Through this approach, we identify and characterize a nanosensor for the chemotherapeutic anthracycline doxorubicin, which provides an up to 17 nm fluorescence red-shift and exhibits an 8 μ M limit of detection, compatible with peak circulatory concentrations of doxorubicin common in therapeutic administration. We demonstrate selectivity of this nanosensor over dacarbazine, a chemotherapeutic commonly co-injected with DOX. Lastly, we demonstrate nanosensor tissue compatibility for imaging of doxorubicin in muscle tissue by incorporating nanosensors into the mouse hindlimb and measuring nanosensor response to exogenous DOX administration. Our results motivate chemometric approaches to nanosensor discovery for chronic imaging of drug partitioning into tissues and towards real-time monitoring of drug accumulation.

TOC GRAPHIC



Chemometric approaches enable high-throughput identification of near-infrared single-walled carbon nanotube optical nanosensors screened against target biomolecule libraries. This method identifies a candidate nanosensor for anthracyclines, which we evaluate for imaging chemotherapeutic doxorubicin in biological tissue.

INTRODUCTION

Availability of optical sensors for quantitative measurements of small molecules is critical to effectively probe biological systems and advance our understanding of biological function, disease, and therapeutic efficacy. While the last several decades of sensor development have focused on organic and supramolecular chemistries for synthesizing new optical sensors,¹ the recent emergence of single-walled carbon nanotubes (SWNTs) as nanoscale sensing elements has led to the development of numerous fluorescence-based sensors selective for biologically-relevant molecular targets including reactive oxygen species, neurotransmitters, and proteins.²⁻⁷ The molecular specificity of SWNT-based nanosensors arises from unique configurations of a polymer-adsorbed phase, or corona phase, on the surface of the SWNT. Interactions between the polymer-phase and a target analyte modulate the innate fluorescence of the SWNT, producing a change in optical signal (**Figure 1A**). Notably, the non-photobleaching fluorescence emission of these nanosensors falls in the short wavelength near-infrared (NIR) region (1000-1500 nm), where absorption and scattering by biological tissues is minimal, making them attractive candidates for long-term or chronic *in vivo* imaging of biological processes.^{8,9}

The primary method of discovery for this class of SWNT-based probe has been through relatively low-throughput screening of candidate nanosensor libraries against potential target analytes of interest. However, SWNTs can be synthesized with up to 15 unique chiralities, each of which exhibits a unique fluorescence excitation and emission profile. Therefore, each SWNT chirality could form distinct polymer corona phases with unique molecular recognition elements, each with contrasting fluorescence responses to an analyte.¹⁰ The complex emission spectra of these samples and their chirality-dependent molecular recognition adds dimensionality to screening

1 data. However, the most common approach to analyzing library screens has been monitoring
2 changes to integrated fluorescence, losing valuable spectral information in the process. Although
3 deconvolution of emission peaks and multivariate statistics have been used to monitor changes
4 in peak intensity or solvatochromic shifts of known nanosensors,¹¹ common chemometric
5 approaches have yet to be implemented to analyze spectra obtained from initial library screens
6 to identify new and unique analyte-nanosensor hits.

7 Here, we present chemometric approaches for analyzing fluorescence emission spectra obtained
8 from screens of candidate SWNT nanosensors. Candidate nanosensors are each functionalized
9 with a different polymer corona phase including polynucleotides, phospholipids, and amphiphilic
10 heteropolymers, and screened against a panel of >40 biologically relevant analytes (see
11 **Supporting Information** for analyte assignments). By implementing distance metric calculations,
12 principal component analysis (PCA), and hierarchical clustering (HC), we demonstrate the rapid
13 and quantitative identification of candidate analytes for nanosensors. These approaches uncover
14 potential structure-response relationships between chemically similar analytes through
15 identification and clustering of analytes that generate similar modulations to the SWNT
16 fluorescence spectrum. We further demonstrate that this platform can be used to identify a novel
17 NIR nanosensor for the detection of the chemotherapeutic doxorubicin (DOX) through a change
18 in the nanosensor fluorescence intensity and up to a 17 nm red-shift upon exposure to DOX.
19 Cardiomyopathy resulting from chemotherapies containing DOX is a primary reason for limiting
20 its cumulative dose, impacting its efficacy as an anticancer treatment.^{12,13} Thus, monitoring DOX
21 biodistribution in tissue using an optical nanosensor may help maximize the therapeutic value of
22 DOX administration while minimizing its cardiotoxicity. As a first step to this end, we demonstrate
23 imaging of DOX in mouse hindlimb tissue with a DOX-responsive SWNT nanosensor to confirm
24 nanosensor functionality in a biological milieu. Our results motivate application of this
25 chemometric nanosensor discovery platform to generate SWNT nanosensors for biomolecule
26 analytes and their translation for use in biological tissues.

27 **MATERIALS AND METHODS**

28 *CANDIDATE NANOSENSOR SYNTHESIS*

29 Soluble suspensions of SWNTs were prepared by combining between 0.2-5 mg of hydrated (5
30 wt% mixed-chirality SWNT (NanoIntegris) in deionized water) with 1 mL solutions of polymer or
31 lipid. DNA samples contained 100 μ M DNA oligo (Integrated DNA Technologies, Inc., standard
32 desalting) in 100 mM NaCl. Phospholipid samples contained 2 mg/mL of 1,2-dipalmitoyl-sn-
33 glycerol-3-phosphoethanolamine-polyethylene glycol (2000) (DPPE-PEG, Avanti Polar Lipids,
34 Inc.) in 1X phosphate buffered saline (PBS) and 0.2 mg SWNT. RITC-PEG-RITC polymer
35 (rhodamine isothiocyanate-polyethylene(5000) glycol-rhodamine isothiocyanate) solutions
36 contained 1 mg polymer, prepared using previously published methods,³ dissolved in 1X (PBS).
37 Solutions were bath sonicated for 10 min followed by probe tip sonication using a 3 mm probe tip
38 at 40-50% amplitude for 10 min. Samples were then centrifuged at 16100 c/g for 30 minutes to
39 pellet insoluble bundles and contaminants and the supernatant containing product was collected.

1
2
3 1 Concentration of SWNT was determined using sample absorbance at 632 nm and the extinction
4 2 coefficient $\epsilon=0.036 \mu\text{g/mL}$.

6 3 *SCREENING, SPECTROSCOPY, AND SINGLE MOLECULE IMAGING*

8 4 SWNT nanosensors (10 $\mu\text{g/mL}$ SWNT in 1X PBS) were initially screened against a library of small
9 5 molecule analytes (1 mM stocks stored in either water or a water/DMSO mixture; 0.1 mM final
10 6 concentration). Each sample was prepared in triplicate. After a 1-hour incubation period at room
11 7 temperature, fluorescence emission spectra were collected using an SCT 320 spectrometer and
12 8 PyLon-IR 1024/1.7 containing a liquid nitrogen cooled InGaAs array detector (Princeton
13 9 Instruments). Nanosensors were excited using a beam-expanded 721 nm diode pumped solid
14 10 state laser (10-500 mW) coupled to an inverted microscope body (Axio Observer, Carl Zeiss)
15 11 containing a custom filter cube set (800 nm SP FESH0800, 900 nm LP dichroic DMLP900R, 900
16 12 nm LP FELH900, ThorLabs) and motorized well plate stage (Marzhauser Wetzlar GmbH & Co.).
17 13 Emission light was collected and relayed to the slit of the spectrometer using plano convex lenses
18 14 coated with antireflective coating AR-3 (ThorLabs). Unless otherwise noted, all samples were
19 15 prepared in 1X PBS. For surface-immobilized single molecule experiments, nanosensors were
20 16 immobilized onto glass coverslip surfaces treated with (3-Aminopropyl)triethoxysilane (APTES,
21 17 10% v/v in ethanol, 2 min incubation followed by wash with PBS) by incubation for 3 min at 10
22 18 $\mu\text{g/mL}$ concentration followed by a rinse with 1X PBS. Single-nanosensor imaging experiments
23 19 consisted of recording fluorescence images while washing solutions containing 0.1 mM target
24 20 analyte in 1X PBS onto the immobilized nanosensors, followed by washing with 1X PBS. Videos
25 21 were captured using a NIRvana 640x512 InGaAs array camera (Princeton Instruments) and a
26 22 100x alpha plan-apochromat oil immersion objective with NA 1.46 (Zeiss).

31 23 *CHEMOMETRIC ANALYSIS*

32 24 Spectra obtained from fluorescence screens were normalized to the mean of the peak intensity
33 25 for the (7,6) chirality SWNT of control measurements. Analysis was performed using JMP
34 26 software suite (SAS Institute Inc.) and custom scripts written using MATLAB (R2017b, The
35 27 Mathworks, Inc.) and its built-in functions for principal component analysis (`pca()`) and
36 28 hierarchical clustering (`cluster()`, `linkage()`) with default parameters, unless otherwise
37 29 noted. Curve fitting for DOX titration data was performed with the `fit()` function in MATLAB
38 30 using a non-linear least squares method. The fluorescence intensity and peak wavelength of the
39 31 nanosensor was assumed to be proportional to the fraction of binding sites occupied by DOX.¹⁴
40 32 For comparison of nanosensor response to doxorubicin (HCl salt, Fisher BioReagents, Fisher
41 33 Scientific), epirubicin (HCl salt, Selleck Chemical LLC), and daunorubicin (HCl salt, Calbiochem,
42 34 MilliporeSigma), each emission spectrum was approximated as the linear combination of the
43 35 spectrum for a bare nanosensor and the spectrum for a nanosensor saturated in anthracycline,
44 36 $S = \alpha S_{\text{initial}} + \beta S_{\text{saturated}}$. The fraction of bare nanosensor (α) and anthracycline bound nanosensor
45 37 (β) was calculated by a least squares method `lsqnonneg()` in MATLAB (R2017b, The
46 38 Mathworks, Inc.).

52 39 *DOX IMAGING IN HUMAN BLOOD PLASMA AND MOUSE TISSUE*

53 40 Pooled normal human blood plasma with 0.15% disodium ethylenediaminetetraacetic acid
54 41 (EDTA) anticoagulant was thawed and mixed 1:1 with 10 $\mu\text{g/mL}$ SWNT nanosensor. The

1
2
3 1 fluorescence emission spectrum was compared to a 1:1 mixture of 1X PBS and 10 $\mu\text{g}/\text{mL}$ SWNT
4 2 nanosensor. Concentrated doxorubicin solutions were added to both samples at a final
5 3 concentration of 0.1 mM. Each sample was prepared in triplicate. Mouse hind leg muscle tissue
6 4 was harvested following euthanasia and rapidly frozen in liquid nitrogen for preservation until use.
7 5 SWNT nanosensor was loaded into tissue by incubation for 10 min in a 1X phosphate buffered
8 6 saline (PBS) solution containing 10 mg/L nanosensor followed by thorough rinsing with 1X PBS.
9 7 Images and emission spectra of the tissue submerged in a bath of 1X PBS were obtained using
10 8 a 20x plan-apochromat objective with NA 0.8 (Zeiss). DOX was added to the bath to a final
11 9 concentration of 0.1 mM and allowed to incubate for 10 min prior to collecting fluorescence
12 10 spectra.


11 RESULTS AND DISCUSSION

12 CHEMOMETRIC ANALYSIS OF SIMULATED NANOSENSOR FLUORESCENCE DATA

13 To evaluate different chemometric methods for analyzing SWNT candidate nanosensor
14 fluorescence response data, we first constructed a simulated dataset representing expected
15 results from a SWNT candidate nanosensor library screened against a chemical analyte library.
16 The simulated dataset is comprised of 100 sample spectra each containing 4 Gaussian peaks to
17 simulate the contributions of a sample containing a mixture of 4 different SWNT chiralities,
18 comparable to the fluorescence emissions of (6,5), (10,2), (7,6), and (8,7) SWNTs. Should a
19 candidate SWNT nanosensor respond to a particular analyte, we expect a change in the
20 fluorescence emission spectra. These spectral changes can include (i) uniform fluorescence
21 signal enhancement, (ii) uniform quenching, (iii) chirality-dependent enhancement and/or
22 quenching, or (iv) red or blue shifting in peak wavelength.¹¹ As such, we included an example of
23 each expected fluorescence response signal in our simulated dataset (**Figure 1B**): Uniform mild
24 increase (*Response 1*), single-chirality increase (*Response 2*), uniform strong increase
25 (*Response 3*), uniform wavelength shift (*Response 4*), no change (*Response 5*), asymmetric
26 chirality-dependent change (*Response 6*), uniform decrease (*Response 7*), and single-chirality
27 decrease (*Response 8*). Random noise was added to each simulated spectrum (0-5% total signal)
28 along with systematic variance (0-10% total signal) corresponding to expected experiment-to-
29 experiment variations. The completed simulated dataset is plotted as a heatmap, where color
30 indicates intensity values (**Figure 1B**).

31 With this simulated dataset, our goal was to explore statistical methods for identifying analytes
32 that significantly and uniquely modulate the candidate SWNT nanosensor fluorescence emission,
33 then to categorize analytes that induce similar responses. Using several different distance metrics
34 (**Figure 1C**), we determined an effective fluorescence response signal, s , by calculating the mean
35 pairwise distance for each analyte, s_i , and normalizing by the mean signal for all analytes, $\sum_i^N s_i/N$.
36 (See **Supporting Information** for details on the metrics used). For samples that underwent a
37 change in their fluorescence emission spectra, values of s calculated greater than $3\sigma_{SD}$ were
38 deemed significant and considered a hit candidate. These hits included samples exhibiting
39 changes to fluorescence emission intensity as well as solvatochromic shifts. We found that the

1 magnitude of s_i was dependent on the choice of distance metric and the type of fluorescence
 2 response (**Figure 1D**). Based on the results of these simulated datasets, we show that
 3 calculations of pairwise distances between emission spectra can be used to rapidly identify
 4 potential targets from a large library screen that produce intensity changes, solvatochromic shifts,
 5 or chirality-dependent responses to nanosensor fluorescence.



6
 7 **Figure 1** (A) Schematic depicting the composition of a near-infrared fluorescent SWNT nanosensor. Binding of small
 8 molecules, such as an anthracycline, modulates SWNT fluorescence emission by perturbing the polymer-adsorbed
 9 phase. (B) Simulated emission spectra for SWNT nanosensor candidates after addition of different analytes. Dashed
 10 spectra correspond to original fluorescence emission. Solid lines correspond to fluorescence emission spectra of the
 11 nanosensor after analyte addition: Uniform mild increase (*Response 1*), single-chirality increase (*Response 2*), uniform
 12 strong increase (*Response 3*), uniform wavelength shift (*Response 4*), no change (*Response 5*), asymmetric chirality-
 13 dependent change (*Response 6*), uniform decrease (*Response 7*), and single-chirality decrease (*Response 8*). (C)
 14 Simulated library screen dataset containing 100 spectra displayed as a heatmap. Numbered arrows correspond to the
 15 analyte spectra shown in (A). (D) Response signals were calculated for each analyte using the different pairwise metric
 16 calculations. A potential signal hit or outlier is determined if the signal is greater than $3\sigma_{SD}$.

1
2
3 1
4
5 2 Another powerful approach for rapidly analyzing spectra from library screens is principal
6 3 component analysis (PCA), a multivariate technique employed to simplify complex chemical
7 4 spectra and reveal underlying trends.^{15–17} Performing PCA on the simulated SWNT nanosensor
8 5 spectra identifies an orthonormal set of variables (principal components) composed of linear
9 6 combinations of the original variables (wavelengths) that maximize variance within the dataset.
10 7 Subsequent components are chosen to maximize variance while remaining orthonormal to the
11 8 previous components. A library of SWNT nanosensor response spectra can then be represented
12 9 as vectors in a space comprised of the principal components that account for the most variance
13 10 in the dataset. This simplification reduces dimensionality of the data while capturing the relevant
14 11 changes to the height and position of spectral peaks without the computationally intensive cost of
15 12 chirality deconvolution and peak fitting. **Figure 2A** outlines the results of performing PCA on the
16 13 simulated SWNT nanosensor spectra dataset. Plotting each spectrum in principal component
17 14 (PC) space demonstrates how this approach identifies outlying spectra. While most spectra are
18 15 clustered around (0,0), spectra exhibiting a change in intensity or peak wavelength are distinctly
19 16 separated. Each PC represents a particular characteristic of the spectra as represented by the
20 17 component loadings. Analyzing the loading plots shows PC1 represents a uniform increase or
21 18 decrease in intensity, PC2 represents a wavelength shift, and PC3 represents a non-uniform, or
22 19 chirality-dependent, intensity change. Additionally, PCA identifies responses that are
23 20 distinguishable from one another, a property leveraged previously for multiplexed sensing.¹¹ For
24 21 example, two nanosensors can be used simultaneously provided one undergoes a wavelength
25 22 change, and the other an intensity change when bound to their respective analytes. Considering
26 23 the simulated nanosensors in **Figure 2A**, a plot of the combined nanosensor spectra in (PC1,
27 24 PC2) space can resolve and quantify the response of each nanosensor by projection onto its
28 25 respective PC. This approach makes PCA particularly useful for screening nanosensor libraries
29 26 to identify pairs for multiplexed sensing.

30
31 27 Candidate nanosensor library screens can be further organized by clustering to identify analyte
32 28 similarities. Hierarchical clustering (HC) assigns data into clusters based on the similarity of
33 29 analyte modulation of SWNT fluorescence spectra. For example, in the simulated nanosensors
34 30 library screen, HC is implemented to classify responses to different analytes into groups or
35 31 clusters based on the similarity between spectra calculated using distance metrics. Groups are
36 32 generated by merging similar spectra such that the increase in variance between members of the
37 33 new group is minimized (Ward's method). Using different distance metric calculations, we
38 34 clustered the simulated library screening data into groups of analytes that produced similar
39 35 fluorescence responses (**Figure 2B**). Clustering analytes by the fluorescence response they
40 36 induce on the SWNT nanosensor candidates provides insight into similarities between analyte
41 37 properties and can inform mechanisms of interaction with the SWNT and its corona phase.





Figure 2. (A) Each simulated spectrum is plotted in principal component space of PC1, PC2, and PC3. A plot of the component loadings as a function of candidate SWNT nanosensor wavelength reveals the spectral characteristic for the first three principal components. (B) Hierarchical clustering dendrograms calculated with different pairwise distance metrics cluster similar analytes based on their modulation of SWNT fluorescence emission spectra.

CHEMOMETRIC ANALYSIS OF DNA-, POLYMER- AND PHOSPHOLIPID SWNT NANOSENSOR LIBRARIES

To evaluate the efficacy of the above methods for curating information from real SWNT nanosensor candidate screening data, we prepared a library comprised of 10 SWNT nanosensors with distinct wrappings: 8 nanosensors synthesized with single stranded DNA oligo corona phases, 1 nanosensor with a heteropolymer corona, and 1 nanosensor with a phospholipid corona (see **Supporting Information** for details). Each SWNT nanosensor was screened against a panel of >40 biologically-relevant small molecule analytes including sugars, neurotransmitters, nucleosides, small molecule drugs, and vitamins (**Figure 3, Figure S1**). We included target analytes formerly shown to modulate SWNT fluorescence to ensure our approach could identify previously validated molecular analytes. These 'known-responsive' analytes were included as positive controls and include dopamine, ascorbic acid, thyroxine, melatonin, and riboflavin. Representative spectra compiled from DNA-corona nanosensor screens are shown in **Figure 3A**. The spectra are represented as heat maps, where each row represents a single SWNT fluorescence spectrum after exposure to an analyte, and color represents fluorescence intensity after normalization to the maximum intensity of the average control spectrum. Peaks in the emission spectra correspond to SWNT chiralities present in each sample. To identify analytes that modulated the SWNT nanosensor fluorescence, distance matrices were calculated using each distance metric (**Figure S1**) and subsequently used to calculate the fluorescence response

1 signal, s , for each analyte (**Figure 3B**). Lastly, analyte “hits” ($s > 3\sigma_{SD}$) calculated using each
 2 distance metric were compiled for SWNT nanosensors and visualized as a radial scatter plot,
 3 where spot size and radial position indicate the total number of “hits” for each analyte (**Figure**
 4 **3C**). Results for all candidate nanosensors tested are presented in the **Supporting Information**.

5




6

7 **Figure 3** (A) Representative emission spectra heat maps for two DNA-SWNT nanosensor candidates upon exposure
 8 to an analyte library. Horizontal axes represent wavelength, vertical axes denote a particular analyte, and color
 9 represents normalized fluorescence intensity. Each analyte sample was screened in triplicate. (B) Response signal, s
 10 (vertical axes), for each spectrum (horizontal axes) calculated using different distance metrics. (C) Radial plots depicting
 11 analyte “hits” for the two SWNT nanosensors. The radial position and size of the circles scale with the total number of
 12 “hits” ($s > 3\sigma_{SD}$) compiled from the combined results for all distance metrics.

13 For DNA-SWNT candidate nanosensor screens, we confirmed that previously known analytes
 14 elicit the predicted fluorescence responses on their respective SWNT nanosensors, such as the
 15 RITC-PEG-RITC heteropolymer-SWNT for which our screen confirmed a sensitivity to the
 16 hormone estradiol (**Figure S1**).³ Our approach also revealed new nanosensors with sensitivity to
 17 analytes guanosine, cysteine, and L-DOPA, which each induced a moderate fluorescence
 18 response to DNA-SWNT conjugates in a DNA sequence-specific manner (**Figure S1**).
 19 Additionally, we identify responses of several DNA-SWNT conjugates to analytes thyroxine and
 20 riboflavin, revealing that these analytes broadly impact the fluorescence of DNA-SWNT
 21 conjugates in a manner not specific to DNA sequence.³ We also identify novel responses of select
 22 DNA-SWNT conjugates toward other analytes in the library, including DOX and oxytocin. For
 23 instance, DOX was found to elicit strong fluorescence intensity and wavelength modulation when

1 added to any of the DNA-SWNT conjugates. The response of phospholipid-PEG-wrapped
 2 SWNTs (**Figure S1**) was mildly sensitive to DOX, riboflavin, and thyroxine. However, it was most
 3 sensitive to melatonin, consistent with previous accounts.³



5
 6 **Figure 4.** (A) Principal component analysis for an analyte library screened against the DNA-wrapped SWNT
 7 nanosensor CB13. Each dataset can be plotted using different principal component coordinates. Samples are clustered
 8 using hierarchical clustering computed with centroid distances calculated using a Euclidean metric and normalized
 9 principal components. Cluster assignments for each sample are listed in the Supporting Information. A plot of the
 10 loadings represents the spectral characteristic of each principal component. (B) Hierarchical clustering dendrograms
 11 generated using three different distance metrics for library data acquired for the DNA-wrapped SWNT nanosensor
 12 CB13. DA: dopamine, AA: ascorbic acid, EE: epinephrine, DOX: DOX, NE: norepinephrine, Cy: L-cysteine.

13 The fluorescence response of candidate nanosensors to analytes from the experimental library
 14 was readily quantified with PCA (**Figure 4A**, **Figure S2**). The location of each point in PC space
 15 reflects both the magnitude and nature of the fluorescence response. Plotting the library screening
 16 data in principal component space depicts strong and/or unique analyte responses as outlying
 17 points. A majority of fluorescence responses are clustered around (0,0) in PC space, indicative of
 18 negligible candidate nanosensor fluorescence response, while responses that fall further from the
 19 origin strongly and/or uniquely modulated the SWNT fluorescence. One such 'hit' is shown in
 20 **Figure 4A** depicting representative data for DNA-SWNT nanosensor CB13. The nature of the
 21 response can be inferred from the plot of principal component loadings (**Figure 4A**): PC1
 22 represents an increase in fluorescence emission intensity with longer wavelength SWNT
 23 chiralities showing a larger relative increase in emission than shorter wavelength emitting SWNT
 24 chiralities. Analytes with large PC1 scores include dopamine, ascorbic acid, and norepinephrine,
 25 consistent with previous observations.¹⁴ PC2 and PC3 represent fluorescence responses via both
 26 fluorescence intensity and wavelength shifts. Both DOX (Cluster 6) and riboflavin (Cluster 5) fall
 27 furthest from the plot origins for both PC2 and PC3 axes, consistent with their observed responses
 28 of quenching and shifting fluorescence emission.

1
2
3 1 To investigate the relationship between fluorescence modulation of different analytes eliciting
4 2 similar fluorescence responses, we next performed hierarchical clustering on the spectra library
5 3 using cosine, Chebyshev, and Xcorr metrics. Representative data for the DNA-wrapped SWNT
6 4 nanosensor CB13 is shown in **Figure 4B**. Applying the cosine and Xcorr metrics, we observe that
7 5 all samples containing DOX and riboflavin were clustered separately from the rest of the analyte
8 6 library. Both DOX and riboflavin induced a change in fluorescence emission intensity as well as
9 7 a peak wavelength shift. When applying the Chebyshev metric, both DOX and riboflavin separate
10 8 into a third distinct cluster. Additionally, samples containing dopamine, epinephrine, and ascorbic
11 9 acid are contained in a single cluster, while L-DOPA, melatonin, L-cysteine, norepinephrine, and
12 10 NADH are clustered separately. We next rationalized the observed clustering with prior reports of
13 11 SWNT fluorescence modulation by different classes of analytes. The ability of catecholamines
14 12 (dopamine and epinephrine) and ascorbic acid to brighten the fluorescence of DNA-SWNTs is
15 13 attributed to their redox activity, however, their responses cannot be explained by redox potentials
16 14 alone.¹⁸ L-DOPA, melatonin, and norepinephrine, all of which have an aromatic diol and similar
17 15 redox chemistry,¹⁹ are more polarizable and contain an additional rotatable bond compared to
18 16 dopamine, epinephrine, and ascorbic acid. This suggests a combination of polarizability and
19 17 molecular bond flexibility properties may account for the differences in the fluorescence response
20 18 of DNA-SWNT. Conversely, DOX and riboflavin, in addition to being oxidizing and light absorbing,
21 19 both contain large planar aromatic groups. These chemical properties may contribute to increased
22 20 steric and pi electronic interactions that distinguish the optical response induced on SWNT by
23 21 DOX and riboflavin over the other analytes investigated. These analyte clustering trends were
24 22 similar for the other DNA-wrapped SWNTs examined, with some clusters also containing analytes
25 23 found to moderately modulate SWNT fluorescence, including glutamic acid, estradiol, oxytocin,
26 24 serotonin, ampicillin, creatine, and DOPAC (**Figure S3**). As expected, analytes screened using
27 25 the polymer-wrapped and phospholipid wrapped SWNTs likewise clustered according to their
28 26 impact on SWNT fluorescence modulation. Furthermore, HC was also applied to analytes in PC
29 27 space (**Figure 4A**) to identify distinct clusters far from (0,0), aiding in the identification of
30 28 nanosensors for multiplexing.

31 29 *EVALUATING SWNT NANOSENSORS DOX DETECTION*

32 30 The above chemometric analyses revealed several unique DNA-SWNTs for implementation as
33 31 nanosensors in the selective optical imaging of DOX. Direct in-tissue imaging of DOX during
34 32 chemotherapy can help personalize and monitor dosage levels to minimize damage to cardiac
35 33 tissue while maximizing therapeutic efficacy. Towards this end, we compared the DNA-SWNTs
36 34 identified in analyses above as responsive to DOX and evaluated their responses for use in
37 35 biological tissue. We first compared 12 distinct SWNT nanosensors wrapped in different DNA
38 36 sequences to understand the sequence-dependence of DOX recognition and SWNT nanosensor
39 37 fluorescence modulation. **Figure S1** shows that nearly all DNA-SWNTs exposed to 100 μ M DOX
40 38 experienced a quenching of fluorescence emission intensity. Additionally, DNA-SWNTs exhibiting
41 39 the greatest degree of quenching also experienced up to an 8 nm red-shift in peak emission
42 40 intensity. Curiously, the fluorescence emission of CB4 and CB14 SWNTs were not modulated by
43 41 DOX despite having both a similar nucleobase sequence and spectral shape to responsive
44 42 constructs, such as CB13. A more detailed comparison of each DNA-SWNT preparation revealed
45 43 a weak correlation between DOX response, AT composition, and DNA sequence affinity for the

1
2
3 1 SWNT, as measured by suspension yield (**Figure S4**). These results suggest SWNT surface
4 2 coverage density by DNA plays a role in the conjugate's interaction with DOX, and that differences
5 3 in nucleobase adsorption energy to SWNTs renders certain ssDNA sequences more or less prone
6 4 to fluorescence modulation by DOX.^{20,21} Furthermore, this analysis revealed that CB13-SWNTs,
7 5 which experience both a quench and a shift in fluorescence upon exposure to DOX, was the
8 6 nanosensor construct with the most robust change to its fluorescence emission, making it an
9 7 optimal candidate for DOX detection.

12 8 We next investigated the role of DNA coverage density and nanosensor response to DOX by
13 9 synthesizing CB13-DNA-SWNT constructs with variable DNA surface densities. By changing the
14 10 SWNT:DNA mass ratio from 1:0.8 to 3:0.8 to 5:0.8, we observe a change in both the emission
15 11 spectra of the CB13-DNA-SWNT constructs, as well as differences in the fluorescence response
16 12 to DOX (**Figure 5A**). As the SWNT:DNA mass ratio was increased, the baseline intensity of the
17 13 longer wavelength (larger diameter) SWNT chiralities decreased. Additionally, larger-diameter
18 14 SWNTs experienced a sharp increase in fluorescence emission when exposed to DOX, in
19 15 contrast to the decrease in emission intensity observed for nanosensors prepared using a lower
20 16 SWNT:DNA ratio corona. We posit that decreasing the DNA to SWNT mass ratio causes an
21 17 increased DNA wrapping pitch and exposes a larger proportion of the SWNT surface to the
22 18 aqueous phase and thus susceptible to fluorescence quenching by oxygen, influencing SWNT
23 19 baseline fluorescence emission intensity in a chirality-dependent manner.²²⁻²⁴ In this model, DOX
24 20 binding to the SWNT via hydrophobic and pi-pi stacking interactions²⁵ would displace water,
25 21 protons, and oxygen from the SWNT surface, reversing defect mediated quenching.²⁴ Curiously,
26 22 displacement of solvent from the SWNT surface, and the subsequent change in dielectric
27 23 constant, is expected to induce a blue-shift in fluorescence emission, rather than the red-shift we
28 24 observe.²⁶ We therefore propose an alternative mechanism, whereby DOX modulates nucleobase
29 25 stacking on the nanotube surface, inducing a conformational change in the DNA. Increased
30 26 accessibility of solvent to the SWNT surface induces a red-shift in fluorescence emission,^{27,28}
31 27 while changes to the periodic surface potential on the nanotube surface modulate exciton
32 28 lifetimes, which results in an increase in fluorescence emission.²⁹ This increase in fluorescence
33 29 is likely dependent on the formation of a highly ordered arrangement of the polymer on the SWNT
34 30 surface, corroborated by the dependence on DNA surface coverage density we observe. These
35 31 hypotheses are further corroborated by single-molecule microscopy measurements of individual
36 32 nanosensors (**Figure S6**) to confirm that the fluorescence intensity changes are reversible,
37 33 suggesting a transient, non-covalent interaction with DOX.

44 34 Owing to the robustness of a turn-on fluorescent nanosensor compared to a turn-off readout, we
45 35 further characterized the CB13-DNA-SWNT nanosensor using the 3mg mass ratio, which
46 36 exhibited the largest intensity increase in response to DOX. Time-resolved measurements of the
47 37 fluorescence response to DOX reveals a chirality-dependent fluorescence response of the mixed
48 38 chirality CB13-DNA-SWNT sample (**Figure 5C-D**). (7,6)-chirality SWNTs experience an intensity
49 39 increase and 12 nm red-shift that reaches steady-state after 10 min incubation with DOX. In
50 40 contrast, DOX induces an 8 nm red-shift and quenches the fluorescence of (6,5)-chirality SWNTs
51 41 by 30% and stabilizes within seconds. Using the (7,6)-SWNT emission peak intensity and
52 42 wavelength, we constructed DOX concentration calibration curves for the CB13-SWNT
53 43 nanosensor response (**Figure 5E,F**). Intensity and peak wavelength curves are fit to the Hill

1 equation, used previously to characterize the kinetics of SWNT nanosensors with their analytes.¹⁴
2
3 From Hill equation fits, we estimate dissociation constant (K_D) values for DOX binding to CB13-
4 DNA-SWNT of 48-100 μM for peak intensity, and a K_D of 14-28 μM for peak wavelength. The limit
5 of detection was calculated using $3\sigma_{SD, baseline}$ of a nanosensor control measurement with the fits
6 for intensity and peak wavelength to obtain DOX limit of detection values of 9 μM and 8 μM ,
7 respectively. The sensitivity of the CB13-DNA-SWNT nanosensor therefore approaches peak
8 circulatory concentrations of DOX for common therapeutic administration³⁰ and could reveal areas
9 of overly toxic drug concentrations or drug accumulation in tissue by direct imaging.

9 We explored the selectivity of the CB13-DNA-SWNT by comparing its fluorescence response to
10 two additional anthracycline chemotherapeutic drugs: epirubicin and daunorubicin (**Figure 5G**).
11 Both doxorubicin and epirubicin had a similar impact on the fluorescence emission, producing an
12 intensity increase and red-shift. Similarly, daunorubicin increased the fluorescence intensity but
13 experienced a 6 nm greater redshift than either doxorubicin or epirubicin, meaning the
14 fluorescence response is general to anthracyclines. By performing titrations and modeling the
15 resulting fluorescence emission spectra as a linear combination of spectra for (1) pristine CB13-
16 DNA-SWNT and (2) anthracycline-bound CB13-DNA-SWNT ($S = \alpha S_{initial} + \beta S_{saturated}$), we found
17 daunorubicin had a lower binding affinity ($K_D \sim 100 \mu\text{M}$) to the CB13-DNA-SWNT, despite its
18 greater wavelength shift compared to doxorubicin and epirubicin. We expect that binding affinity
19 depends on the DNA sequence and the resulting corona phase on the SWNT, which could be
20 tuned to select for a particular anthracycline in future library screens. Interestingly, by plotting the
21 sum of the fits ($\alpha + \beta$) (**Figure S7**), we find a large deviation from unity at intermediate
22 concentrations of anthracycline, suggesting the presence of an intermediate conformation state
23 of the corona phase.³¹ Lastly, we observe a negligible fluorescence modulation of CB13-DNA-
24 SWNT upon exposure to the alkylating-agent dacarbazine (DTIC), a chemotherapeutic commonly
25 co-injected with DOX, which demonstrates the specificity of the nanosensor over this potentially
26 interfering analyte (**Figure 5I**).




Figure 5. (A) Fluorescence response ($F-F_0/F_0$) for spectra of CB13 DNA-SWNTs upon addition of 100 μM DOX. Changing the ratio of SWNT:DNA (w/w) alters both the fluorescence emission intensity and response to DOX. 1 mL samples of 100 μM DNA suspending (i) 1 mg (red), (ii) 3 mg (yellow), or (iii) 5 mg (blue) SWNT. Each spectrum represents the average of 3 technical replicate measurements. (B) Fluorescence emission spectra of CB13-DNA-SWNT before addition of ($t=0$), and after 10 min incubation with ($t=10$ min) 100 μM DOX. Time series traces of the (C) (6,5) and (D) (7,6) peaks reveal that the peak wavelength (red) shifts continuously over 10 min while the peak intensity (black) for (6,5) plateaus rapidly compared to (7,6). (E, F) Fluorescence response of normalized intensity (E) and wavelength (F) for the (7,6) chirality peak of CB13-DNA-SWNT versus DOX concentration. Triangles (red) and circles (black) represent separate experimental replicates. Each point is the average of 3 technical replicates with standard deviation as error bars. Curve fits were calculated using non-linear least squares. (G) Fluorescence emission spectra of CB13-DNA-SWNT in the presence of 0.1 mM of the anthracyclines doxorubicin (DOX), epirubicin (EPR) and daunorubicin (DAR). (H) Fraction of pristine SWNT (solid lines) and anthracycline-bound SWNT (dotted lines) calculated from fluorescence emission spectra as a function of concentration for the different anthracyclines. (I) Comparison of the fluorescence response of CB13-DNA-SWNT nanosensor to the chemotherapeutics doxorubicin (DOX) and dacarbazine (DTIC) at 0.1 mM concentration.

1
2
3 1 We lastly evaluate the CB13-DNA-SWNT nanosensor in a preliminary assessment for DOX
4 2 imaging in tissue. The CB13-DNA-SWNT nanosensor, prepared using the optimized SWNT:DNA
5 3 ratio 3:0.8, was first incubated in human blood plasma, followed by the addition of 0.1 mM
6 4 doxorubicin. After a 10-minute incubation, fluorescence emission spectra were collected and
7 5 compared to CB13-DNA-SWNT in plasma without doxorubicin. The presence of blood plasma
8 6 was shown to increase the fluorescence emission of the CB13-DNA-SWNT (**Figure 6A**), which
9 7 is likely the result of blood proteins adsorbing onto the SWNT surface, but the response is notably
10 8 absent of the characteristic wavelength-shift implemented to quantify DOX.^{34,35} Adding
11 9 doxorubicin in the presence of plasma quenches the fluorescence of the SWNT and induces the
12 10 characteristic red-shift in peak emission. Preservation of the solvatochromic response of the
13 11 SWNT allows for quantification of doxorubicin despite the presence of blood plasma proteins. To
14 12 further demonstrate its efficacy, we incorporated CB13-DNA SWNT into muscle tissue excised
15 13 from the hind leg of a mouse by incubating a solution of 10 $\mu\text{g}/\text{mL}$ CB13-DNA-SWNT in 1X PBS
16 14 with the tissue. Near-infrared images of the muscle tissue after incubation with nanosensor
17 15 followed by washing with 1X PBS reveal clear localization of nanosensors within the striated
18 16 tissue (**Figure 6B,C**). Addition of 100 μM DOX to the saline bath containing the nanosensor-
19 17 loaded tissue caused a pronounced red-shift of the nanosensor fluorescence emission spectrum
20 18 integrated across the entire field of view (**Figure 6D**). The 7 nm nanosensor red-shift signal was
21 19 observed 20 min after the addition of DOX to the saline bath, the time required for DOX to diffuse
22 20 into the tissue. The nanosensor red-shift was accompanied by a decrease in fluorescence
23 21 intensity, consistent with the decrease we observed for CB13-DNA-SWNT in blood plasma after
24 22 exposure to doxorubicin driven by the adsorption of proteins onto the SWNT surface. To better
25 23 quantify the solvatochromic shift of the nanosensors, we calculated the ratio of integrated
26 24 fluorescence for long wavelength emission (>1130 nm) to short wavelength emission (<1130 nm),
27 25 which could be implemented into a dual camera setup using a dichroic mirror (**Figure 6E**).
28 26 Addition of 0.1 mM doxorubicin nearly doubles this fluorescence ratio, providing a strong turn-on
29 27 signal for quantitative imaging. Our results demonstrate that SWNT fluorescence wavelength
30 28 shifts provide a robust optical readout for chemotherapeutic drug imaging in the relevant biological
31 29 milieu of muscle tissue.^{5,36} Employing nanosensors for direct monitoring of DOX accumulation in
32 30 biological tissues could offer a route to circumvent the use of tissue biopsies.^{13,32,33}
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6. (A) Impact of human blood plasma on the fluorescence emission spectra of CB13-DNA-SWNT and the resulting change upon addition of 100 μM DOX. (B) Brightfield image of mouse muscle excised from the upper hind leg. (C) NIR image of muscle tissue from the same field of view as B, revealing fluorescence from CB13-DNA-SWNT localized in the muscle tissue. Scale bar is 100 μm . (D) Emission spectra collected from (B) before (black) and after (red) addition of 100 μM DOX to the sample bath. (E) Intensity ratio of long-wavelength fluorescence to short-wavelength fluorescence for CB13-DNA-SWNT in mouse tissue before and after addition of 100 μM DOX.

CONCLUSIONS

This work presents a chemometric approach for analyzing NIR emission spectra obtained from library screens of SWNT nanosensors and identifying SWNT nanosensors with desired fluorescence signals. These methods provide both a rapid, quantitative measure for evaluating potential new nanosensors for biochemical analytes, and a chemometric platform to infer relationships between analyte structure and nanosensor response. Such approaches are increasingly important for nanosensor discovery and understanding interaction mechanisms as high-throughput compatible screening methods become increasingly available. Moreover, we show that application of these methods can successfully identify a new candidate optical nanosensor for the chemotherapeutic DOX, with a wavelength-shifting optical readout that is compatible with imaging in the biological milieu of muscle tissue. We show that changes to both the intensity and wavelength of our near-infrared nanosensor in response to DOX, and its selectivity over co-administered chemotherapeutic dacarbazine, enables imaging of DOX in mouse hindlimb tissue.

Methods for the continuous, real-time measurements of drugs *in vivo* are necessary to facilitate the development of personalized therapies that employ feedback-controlled delivery to improve safety and efficacy. While great strides have been made in monitoring circulatory concentrations of small molecule drugs with high sensitivities and speeds using electrochemical sensors,³⁷

1 recording spatial distribution and accumulation in tissue remains a challenge. Visible wavelength
2 fluorophores lack the tissue-penetrating ability required for *in vivo* monitoring, making tissue
3 biopsy a necessary step for quantifying drugs and metabolites in patients. As such, the approach
4 we demonstrate herein may be leveraged for future generations of SWNT-based nanosensors
5 towards non-invasive, deep-tissue chronic imaging of drug distribution and accumulation.

6 SUPPORTING INFORMATION

7 The Supporting Information is available free of charge on the ACS Publications website: Details
8 and results for analysis of simulated dataset and Figures S1-S7.

9 ACKNOWLEDGEMENTS

10 The authors thank A Beyene and D Yang for providing samples. We acknowledge funding from
11 Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI) (M.P.L), a Stanley
12 Fahn PDF Junior Faculty Grant with Award # PF-JFA-1760 (M.P.L), a Beckman Foundation
13 Young Investigator Award (M.P.L), a FFAR New Innovator Award, a NIH NIDA CEBRA award #
14 R21DA044010 (to M.P.L.), and a DARPA Young Investigator Award (M.P.L). M.P.L. is a Chan
15 Zuckerberg Biohub investigator. J.T.D.O. is supported by an Early Investigator Research Award
16 from the Congressionally Directed Medical Research Program through the US Department of
17 Defense. R.L.P. is supported by an NSF Graduate Research Fellowship. J.T.D.O. and M.P.L.
18 both received support from a SAS Institute-Burroughs Wellcome Fund Collaborative Fellowship.





19 REFERENCES


- 20 (1) You, L., Zha, D., and Anslyn, E. V. (2015) Recent Advances in Supramolecular Analytical
21 Chemistry Using Optical Sensing. *Chem. Rev.* **115**, 7840–7892.
- 22 (2) Jin, H., Heller, D. A., Kalbacova, M., Kim, J.-H., Zhang, J., Boghossian, A. A., Maheshri, N.,
23 and Strano, M. S. (2010) Detection of single-molecule H₂O₂ signalling from epidermal growth
24 factor receptor using fluorescent single-walled carbon nanotubes. *Nat. Nanotechnol.* **5**, 302–309.
- 25 (3) Zhang, J., Landry, M. P., Barone, P. W., Kim, J. H., Lin, S., Ulissi, Z. W., Lin, D., Mu, B.,
26 Boghossian, A. A., Hilmer, A. J., Rwei, A., Hinckley, A. C., Kruss, S., Shandell, M. A., Nair, N.,
27 Blake, S., Şen, F., Şen, S., Croy, R. G., Li, D., Yum, K., Ahn, J. H., Jin, H., Heller, D. A.,
28 Essigmann, J. M., Blankschtein, D., and Strano, M. S. (2013) Molecular recognition using corona
29 phase complexes made of synthetic polymers adsorbed on carbon nanotubes. *Nat. Nanotechnol.*
30 **8**, 959–968.
- 31 (4) Landry, M. P., Ando, H., Chen, A. Y., Cao, J., Kottadiel, V. I., Chio, L., Yang, D., Dong, J., Lu,
32 T. K., and Strano, M. S. (2017) Single-molecule detection of protein efflux from microorganisms
33 using fluorescent single-walled carbon nanotube sensor arrays. *Nat. Nanotechnol.* **12**, 368–377.
- 34 (5) Harvey, J. D., Jena, P. V., Baker, H. A., Zerze, G. H., Williams, R. M., Galassi, T. V., Roxbury,
35 D., Mittal, J., and Heller, D. A. (2017) A carbon nanotube reporter of microRNA hybridization
36 events in vivo. *Nat. Biomed. Eng.* **1**, 0041.

- 1
2
3 1 (6) Bisker, G., Ahn, J., Kruss, S., Ulissi, Z. W., Salem, D. P., and Strano, M. S. (2015) A
4 2 Mathematical Formulation and Solution of the CoPhMoRe Inverse Problem for Helically Wrapping
5 3 Polymer Corona Phases on Cylindrical Substrates. *J. Phys. Chem. C* 119, 13876–13886.
6
7 4 (7) Ulissi, Z. W., Sen, F., Gong, X., Sen, S., Iverson, N., Boghossian, A. A., Godoy, L. C., Wogan,
8 5 G. N., Mukhopadhyay, D., and Strano, M. S. (2014) Spatiotemporal Intracellular Nitric Oxide
9 6 Signaling Captured Using Internalized, Near-Infrared Fluorescent Carbon Nanotube
10 7 Nanosensors. *Nano Lett.* 14, 4887–4894.
11
12 8 (8) Welsher, K., Sherlock, S. P., and Dai, H. (2011) Deep-tissue anatomical imaging of mice using
13 9 carbon nanotube fluorophores in the second near-infrared window. *Proc. Natl. Acad. Sci. U. S. A.*
14 10 108, 8943–8.
15
16 11 (9) Del Bonis-O'Donnell, J. T., Page, R. H., Beyene, A. G., Tindall, E. G., McFarlane, I. R., and
17 12 Landry, M. P. (2017) Dual Near-Infrared Two-Photon Microscopy for Deep-Tissue Dopamine
18 13 Nanosensor Imaging. *Adv. Funct. Mater.* 27, 1702112.
19
20 14 (10) Salem, D. P., Landry, M. P., Bisker, G., Ahn, J., Kruss, S., and Strano, M. S. (2016) Chirality
21 15 dependent corona phase molecular recognition of DNA-wrapped carbon nanotubes. *Carbon N.*
22 16 *Y.* 97, 147–153.
23
24 17 (11) Heller, D. A., Jin, H., Martinez, B. M., Patel, D., Miller, B. M., Yeung, T. K., Jena, P. V.,
25 18 Hobartner, C., Ha, T., Silverman, S. K., and Strano, M. S. (2009) Multimodal optical sensing and
26 19 analyte specificity using single-walled carbon nanotubes. *Nat. Nanotechnol.* 4, 114–120.
27
28 20 (12) Chatterjee, K., Zhang, J., Honbo, N., and Karliner, J. S. (2010) Doxorubicin cardiomyopathy.
29 21 *Cardiology* 115, 155–62.
30
31 22 (13) Rahman, A. M., Yusuf, S. W., and Ewer, M. S. (2007) Anthracycline-induced cardiotoxicity
32 23 and the cardiac-sparing effect of liposomal formulation. *Int. J. Nanomedicine* 2, 567–83.
33
34 24 (14) Kruss, S., Landry, M. P., Vander Ende, E., Lima, B. M. A., Reuel, N. F., Zhang, J., Nelson,
35 25 J., Mu, B., Hilmer, A., and Strano, M. (2014) Neurotransmitter detection using corona phase
36 26 molecular recognition on fluorescent single-walled carbon nanotube sensors. *J. Am. Chem. Soc.*
37 27 136, 713–724.
38
39 28 (15) Bro, R., and Smilde, A. K. (2014) Principal component analysis. *Anal. Methods* 6, 2812–
40 29 2831.
41
42 30 (16) Stewart, S., Ivy, M. A., and Anslyn, E. V. (2014) The use of principal component analysis and
43 31 discriminant analysis in differential sensing routines. *Chem. Soc. Rev.* 43, 70–84.
44
45 32 (17) Jaumot, J., Eritja, R., Navea, S., and Gargallo, R. (2009) Classification of nucleic acids
46 33 structures by means of the chemometric analysis of circular dichroism spectra. *Anal. Chim. Acta*
47 34 642, 117–126.
48
49 35 (18) Polo, E., and Kruss, S. (2016) Impact of Redox-Active Molecules on the Fluorescence of
50 36 Polymer-Wrapped Carbon Nanotubes. *J. Phys. Chem. C* 120, 3061–3070.
51
52 37 (19) Mark, H. B., Atta, N., Ma, Y., Petticrew, K., Zimmer, H., Lunsford, S., Rubinson, J., and Galal,
53 38 A. (1995) The electrochemistry of neurotransmitters at conducting organic polymer electrodes:
54 39 electrocatalysis and analytical applications. *Bioelectrochemistry Bioenerg.* 38, 229–245.
55
56 40 (20) Das, A., Sood, A. K., Maiti, P. K., Das, M., Varadarajan, R., and Rao, C. N. R. (2008) Binding
57
58
59
60

- 1
2
3 1 of nucleobases with single-walled carbon nanotubes: Theory and experiment. *Chem. Phys. Lett.*
4 2 453, 266–273.
5
- 6 3 (21) Sarmah, A., and Roy, R. K. (2013) Understanding the Interaction of Nucleobases with Chiral
7 4 Semiconducting Single-Walled Carbon Nanotubes: An Alternative Theoretical Approach Based
8 5 on Density Functional Reactivity Theory. *J. Phys. Chem. C* 117, 21539–21550.
9
- 10 6 (22) Strano, M. S., Huffman, C. B., Moore, V. C., O'Connell, M. J., Haroz, E. H., Hubbard, J.,
11 7 Miller, M., Rialon, K., Kittrell, C., Ramesh, S., Hauge, R. H., and Smalley, R. E. (2003) Reversible,
12 8 Band-Gap-Selective Protonation of Single-Walled Carbon Nanotubes in Solution. *J. Phys. Chem.*
13 9 *B* 107, 6979–6985.
14
- 15 10 (23) Dukovic, G., White, B. E., Zhou, Z., Wang, F., Jockusch, S., Steigerwald, M. L., Heinz, T. F.,
16 11 Friesner, R. A., Turro, N. J., and Brus, L. E. (2004) Reversible surface oxidation and efficient
17 12 luminescence quenching in semiconductor single-wall carbon nanotubes. *J. Am. Chem. Soc.* 126,
18 13 15269–15276.
19
- 20 14 (24) Salem, D. P., Gong, X., Liu, A. T., Koman, V. B., Dong, J., and Strano, M. S. (2017) Ionic
21 15 Strength-Mediated Phase Transitions of Surface-Adsorbed DNA on Single-Walled Carbon
22 16 Nanotubes. *J. Am. Chem. Soc.* 139, 16791–16802.
23
- 24 17 (25) Liu, Z., Fan, A. C., Rakhra, K., Sherlock, S., Goodwin, A., Chen, X., Yang, Q., Felsher, D.
25 18 W., and Dai, H. (2009) Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo
26 19 cancer therapy. *Angew. Chemie - Int. Ed.* 48, 7668–7672.
27
- 28 20 (26) Choi, J. H., and Strano, M. S. (2007) Solvatochromism in single-walled carbon nanotubes.
29 21 *Appl. Phys. Lett.* 90, 223114.
30
- 31 22 (27) Heller, D. A., Jeng, E. S., Yeung, T.-K., Martinez, B. M., Moll, A. E., Gastala, J. B., and Strano,
32 23 M. S. (2006) Optical detection of DNA conformational polymorphism on single-walled carbon
33 24 nanotubes. *Science* 311, 508–11.
34
- 35 25 (28) Harvey, J. D., Baker, H. A., Mercer, E., Budhathoki-Uprety, J., and Heller, D. A. (2017)
36 26 Control of Carbon Nanotube Solvatochromic Response to Chemotherapeutic Agents. *ACS Appl.*
37 27 *Mater. Interfaces* 9, 37947–37953.
38
- 39 28 (29) Beyene, A. G., Alizadehmojarad, A. A., Dorlhiac, G., Streets, A. M., Kral, P., Vuković, L., and
40 29 Landry, M. P. (2018) Ultralarge Modulation of Single Wall Carbon Nanotube Fluorescence
41 30 Mediated by Neuromodulators Adsorbed on Arrays of Oligonucleotide Rings. *bioRxiv* 351627.
42
- 43 31 (30) Barpe, D. R., Rosa, D. D., and Froehlich, P. E. (2010) Pharmacokinetic evaluation of
44 32 doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of
45 33 dose adjustment by different indexes of body mass. *Eur. J. Pharm. Sci.* 41, 458–463.
46
- 47 34 (31) van Stokkum, I. H. M., and Liptenok, S. P. (2014) Quantitative Fluorescence Spectral
48 35 Analysis of Protein Denaturation, pp 43–51. Humana Press, Totowa, NJ.
49
- 50 36 (32) Iverson, N. M., Barone, P. W., Shandell, M., Trudel, L. J., Sen, S., Sen, F., Ivanov, V., Atolia,
51 37 E., Farias, E., McNicholas, T. P., Reuel, N., Parry, N. M. A., Wogan, G. N., and Strano, M. S.
52 38 (2013) In vivo biosensing via tissue-localizable near-infrared-fluorescent single-walled carbon
53 39 nanotubes. *Nat. Nanotechnol.* 8, 873–880.
54
- 55 40 (33) Stewart, D. J., Grewaal, D., Green, R. M., Mikhael, N., Goel, R., Montpetit, V. A., and
56
57
58
59
60

- 1
2
3 1 Redmond, M. D. (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart
4 2 and other tissues. *Anticancer Res.* 13, 1945–52.
5
6 3 (34) Gong, X., Sharma, A. K., Strano, M. S., and Mukhopadhyay, D. (2014) Selective Assembly
7 4 of DNA-Conjugated Single-Walled Carbon Nanotubes from the Vascular Secretome. *ACS Nano*
8 5 8, 9126–9136.
9
10 6 (35) Ge, C., Du, J., Zhao, L., Wang, L., Liu, Y., Li, D., Yang, Y., Zhou, R., Zhao, Y., Chai, Z., and
11 7 Chen, C. (2011) Binding of blood proteins to carbon nanotubes reduces cytotoxicity. *Proc. Natl.*
12 8 *Acad. Sci. U. S. A.* 108, 16968–73.
13
14 9 (36) Jena, P. V., Roxbury, D., Galassi, T. V., Akkari, L., Horoszkó, C. P., Iaea, D. B., Budhathoki-
15 10 Uprety, J., Pipalia, N., Haka, A. S., Harvey, J. D., Mittal, J., Maxfield, F. R., Joyce, J. A., and
16 11 Heller, D. A. (2017) A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux. *ACS*
17 12 *Nano* 11, 10689–10703.
18
19 13 (37) Arroyo-Currás, N., Somerson, J., Vieira, P. A., Ploense, K. L., Kippin, T. E., and Plaxco, K.
20 14 W. (2017) Real-time measurement of small molecules directly in awake, ambulatory animals.
21 15 *Proc. Natl. Acad. Sci.* 114, 645–650.
22
23 16
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A1
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20**B****D****C**

A**B**